This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Google Scholar Articles by Ding, J. H. Articles by Morris, D. L. PubMed PubMed Citation Articles by Ding, J. H. Articles by Morris, D. L.

Feasibility of ablation as an alternative to surgical metastasectomy in patients with unresectable sarcoma pulmonary metastases

^a Department of Surgery, St George Hospital, University of New South Wales, Level 3 Pitney Building, Gray Street, Kogarah, NSW 2217, Sydney, Australia
^b Department of Radiology, St George Hospital, Kogarah, NSW 2217, Sydney, Australia

*Corresponding author. Tel.: +(02) 9113 2070; fax: +(02) 9113 3997.

E-mail address: david.morris{at}unsw.edu.au (D.L. Morris).

Percutaneous radiofrequency ablation (RFA) is an alternate treatment modality for pulmonary metastasis in non-surgical candidates. Four patients not suitable for surgery underwent percutaneous RFA for pulmonary metastases from leiomyosarcoma. Success of RFA was assessed with computed tomography (CT). The median length from the radiographic diagnosis of metastatic pulmonary disease (CT-scan) from the primary tumor diagnosis was 67.0 months with a range of 15.0–81.0 months. The median disease free interval following RFA was 19.0 months with a range of 4.0–35.0 months. Three of four patients underwent the procedure uneventfully. RFA is a safe and minimally invasive intervention in non-surgical candidates with sarcoma pulmonary metastases.

Key Words: Leiomyosarcoma; Pulmonary metastases; Radiofrequency ablation; Sarcoma